Eli Lilly and Company $LLY Shares Sold by Insigneo Advisory Services LLC

Insigneo Advisory Services LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,934 shares of the company’s stock after selling 339 shares during the period. Insigneo Advisory Services LLC’s holdings in Eli Lilly and Company were worth $4,626,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at about $27,000. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $31,000. Blume Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after acquiring an additional 14 shares during the period. IMG Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $35,000. Finally, TD Capital Management LLC increased its stake in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $1,058.05 on Monday. The stock has a market capitalization of $1.00 trillion, a price-to-earnings ratio of 69.15, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,066.65. The stock’s fifty day simple moving average is $855.89 and its 200-day simple moving average is $787.81.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the prior year, the business posted $1.18 earnings per share. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Monday. UBS Group raised their target price on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a report on Friday, November 7th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. BMO Capital Markets raised their price target on Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,027.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.